A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Inclusion Criteria:

- Pancreas cancer that cannot be removed by surgery OR that has spread to a new site in
your body.

- You must have one tumor that can be physically measured or scanned by the doctor.

- You have not had any chemotherapy, immunotherapy, biologic therapy, or hormonal
therapy for pancreas cancer, including 5-FU.

- You cannot have any radiation for 4 weeks before starting this study, and you cannot
have radiation to the whole pelvis.

Exclusion Criteria:

- Treatment with any medication or device that has not been approved by regulatory
agencies, like the FDA, at the time you enter the study.

- Documentation that the cancer has spread to your brain.

- Pregnant or breastfeeding.

- A second primary cancer.

- Unable to stop aspirin or non-steroidal anti-inflammatory agents (like ibuprofen) for
5-8 days.